Pericles Calias has joined to-BBB technologies BV, a Netherlands-based drug delivery company, as senior vice president for translational medicine. In this role he will be responsible for accelerating the development of the company’s preclinical portfolio of compounds for the treatment of brain diseases. Dr Calias previously led the development of CNS protein replacement therapies at Shire Plc. Prior to this, he was a member of the founding teams of the ocular companies Eyetech and Eyegate Pharmaceuticals Inc. He will be based in Boston, Massachusetts, US.
To-BBB announced the appointment on 30 June 2014
Copyright 2014 Evernow Publishing Ltd